| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA670: Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor |
|
Medicine details |
|
| Medicine name | brigatinib (Alunbrig®) |
| Formulation | 30 mg, 90 mg and 180 mg film-coated tablet |
| Reference number | 3795 |
| Indication | As monotherapy for treatment of adult patients with anaplastic lymphoma kinase (ALK) positive advanced non small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor |
| Company | Takeda UK Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 23/05/2020 |
| NICE guidance | |